Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
COLLEGIUM PHARMACEUTICAL, INC | Director | Common Stock | 50.3K | $1.54M | $30.52 | Feb 10, 2025 | Direct |
Akebia Therapeutics, Inc. | Director | Common Stock | 48.6K | $59.4K | $1.22 | Jun 2, 2021 | Direct |
Avalo Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 50K | Mar 25, 2025 | Direct | ||
SYNLOGIC, INC. | Director | Stock Option (right to buy) | 30K | Jun 22, 2023 | Direct | ||
Trevi Therapeutics, Inc. | Director | Nonstatutory Stock Option (right to buy) | 30K | Jun 13, 2024 | Direct | ||
Akebia Therapeutics, Inc. | Director | Stock Option (Right to buy) | 20.1K | Jun 2, 2021 | Direct | ||
Biohaven Ltd. | Director | Stock Option (Right to Buy) | 16.6K | Apr 30, 2024 | Direct | ||
Biohaven Pharmaceutical Holding Co Ltd. | Director | Restricted Share Unit Award | 0 | Oct 3, 2022 | Direct | ||
Biohaven Pharmaceutical Holding Co Ltd. | Director | Stock Options (Right to Buy) | 0 | Oct 3, 2022 | Direct |